On June 9, Insilico Medicine fell 5.43% in regular trading, trading at 33.92 HKD/share, with trading volume of 103 million HKD.

On the news front, the company's cornerstone investors and employee restricted shares lock-up period is set to expire on June 29, at which point approximately 453 million shares — representing 81.25% of total share capital — will become available for trading. Market concerns over potential selling pressure from these shareholders have intensified ongoing disposals. The stock has already seen a cumulative decline of nearly 40% over the past month amid Abu Dhabi secondary listing expectations falling through and the approaching unlock window.

Meanwhile, the Life Sciences Tools and Services sector declined broadly, with WUXI APPTEC down 6.02%, GENSCRIPT BIO down 4.80%, WUXI XDC down 4.15%, WUXI BIO down 4.08%, and XTALPI down 3.38%, amplifying the stock's losses through sector-wide selling pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)